Pacira Pharmaceutical Inc., Parsippany, N.J., priced its previously announced public offering of 1.6 million shares of its common stock at a public offering price of $64 each. Read More
Forest Laboratories Inc., of New York, and Almirall SA, of Barcelona, Spain, said they recently received feedback from the FDA regarding the fixed-dose combination of aclidinium and formoterol and, while no new issues have arisen, will need further discussion with the agency to address questions related to chemistry, manufacturing and control. Read More
Aegerion Pharmaceuticals Inc., of Cambridge, Mass., said patient enrollment was initiated in Japan in a phase III trial of lomitapide as an adjunct treatment to reduce low-density lipoprotein cholesterol (LDL-C) in Japanese patients with homozygous familial hypercholesterolemia (HoFH). Read More
Lorus Therapeutics Inc., of Toronto, said preclinical data for LOR-253, its lead cancer agent, demonstrated the ability of the compound to induce apoptosis in blood cancer cell lines, including acute myeloid leukemia (AML) cells, in vitro. Read More
DBV Technologies SA, of Bagneux, France, said it inked a research collaboration with the French National Genotyping Center (CND) at the French Alternative energies and atomic energy commission (CEA), which analyzes gene regulation and epigenetics, specifically DNA methylation. Read More
Just a year out of the gate, Atlas Venture-backed Spero Therapeutics LLC snagged Roche AG as a partner to develop anti-infectives for drug-resistant bacterial infections, targeting a pathway that involves both virulence and persistence of gram-negative bacteria such as Pseudomonas aeruginosa (P. aeruginosa). Read More
SAN DIEGO – At a session on Application of Nanotechnology to the Treatment of Cancer Patients, the presenters showed multiple ways in which nanotechnology could improve cancer treatment and diagnostics. If, that is, the technology can make it onto pharma's priority list. Read More
"It's not the usual model," explained Mark Gurney, CEO of Tetra Discovery Partners LLC, which is collaborating with the Broad Institute's Stanley Center for Psychiatric Research on drugs that might help cognitive impairment in schizophrenia. Read More
Drugmakers' love for the FDA's orphan drug program burnt brightly in 2013. The agency granted three-quarters of the record 346 requests for orphan designations in fiscal 2013 and approved 33 orphan drugs for sale. Read More
